• Tiziana Life Sciences dosed the last patient in its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.
• Top-line results have not been presented yet; the readout is expected in late Q3 or early Q4 2026.
• Data are planned for presentation at the ACTRIMS-ECTRIMS meeting in Toronto in October 2026.
• The study is designed to assess whether the drug can reduce brain inflammation signals, support clinical function, and maintain an acceptable safety profile versus placebo.
• The milestone moves the program into the key results phase, shaping next-step development decisions for a condition with limited treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250700OMX_____CNEWS_EN_GNW9752525_en) on June 25, 2026, and is solely responsible for the information contained therein.